comparemela.com

Latest Breaking News On - Bio pharma inc - Page 2 : comparemela.com

BridgeBio Pharma : BBIO – Acoramidis AG10 TTR – ISA 2024 – Higher risk of mortality in previously hospitalized patients

Higher Risk of Mortality in Previously Hospitalized Patients: Insights From ATTRibute-CM Ahmad Masri1, Michele Emdin2, Keyur Shah3, Kunal Bhatt4,.

Australia
Portland
Oregon
United-states
Dallas
Texas
Brisbane
Queensland
San-francisco
California
Palo-alto
Perth

BridgeBio Pharma : BBIO Acoramidis (AG10) TTR ISA 2024 Featured research in the ATTR CM landscape

Primecap Management Co. CA Boosts Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)

Primecap Management Co. CA boosted its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the quarter. Primecap Management […]

Wellington
New-zealand-general
New-zealand
Bridgebio-pharma
Bio-pharma
Randalw-scott
Primecap-management-co
Norges-bank
Bio-pharma-inc
Northern-trust-corp
Jpmorgan-chase-co
Nasdaq

BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Primecap Management Co. CA

Primecap Management Co. CA lifted its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 0.6% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 944,000 shares of the company’s stock after acquiring an additional 5,300 shares during the period. Primecap […]

Bio-pharma
Randalw-scott
Bio-pharma-inc
Assetmark-inc
Primecap-management-co
Bridgebio-pharma-company-profile
Atria-wealth-solutions-inc
Commerce-bank
Nasdaq
Jpmorgan-chase-co
Cantor-fitzgerald

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting

BridgeBio Pharma to Present Additional Analyses from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) at the 2024 ISA Meeting
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United-kingdom
Minnesota
United-states
Oregon
Vancouver
British-columbia
Canada
Jean-francois-tamby
Kevinm-alexander
Margot-davis
Juliand-gillmore
Brettw-sperry
© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.